[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exudative-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exudative-macular-degeneration":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100401198","phase-2-mmp-9-inhibition-for-recalcitrant-wet-amd-100401198",false,"NCT04504123","MMP-9 Inhibition for Recalcitrant Wet AMD","MMP-9 Inhibition for Recalcitrant Wet Age-Related Macular Degeneration (AMD)","Inclusion Criteria:\n\n* Wet age-related macular degeneration (wAMD);\n* Solely treated with anti-VEGF IVI for active CNV due to wAMD. However, enrolled patients can have other retinal pathologies such as diabetic retinopathy or vein occlusion for which they are not being treated with anti-VEGF IVI;\n* Must have persistent sub-retinal with or without intra-retinal fluid due to active CNV from wAMD despite receiving at least three consecutive injections with any anti-VEGF agent;\n* Must not have encountered previous side effects from tetracycline medications.\n\nExclusion Criteria - Ocular:\n\n* History of uveitis (including endophthalmitis) or presence of intraocular inflammation;\n* Presence of significant epiretinal membrane or macular hole causing distortion of macular anatomy;\n* Presence of media opacity preventing discerning of fluid on OCT;\n* Any prior ophthalmic surgery (including YAG or retinal laser) within the previous 3 months or anticipated need for any ophthalmic surgery (including cataract extraction) for 9 months following randomization;\n* History of peribulbar corticosteroid injection to the studied eye or the fellow eye within the past 6 months;\n* History of intravitreal triamcinolone acetonide injection to the studied eye within the past 4 months;\n* An ocular condition (other than AMD) is present in the studied eye that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g., retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, and Irvine-Gass syndrome);\n* CNV due to causes other than wAMD;\n* Inability to follow up at the 6th and 9th months time points after recruitment;\n* Missing two or more consecutive injections during the six months treatment period;\n* Patient requiring imminent need for IVI anti-VEGF medication switch or another treatment intervention, such as photodynamic therapy, during the 9 months trial period;\n* Presence of fluid associated with geographic atrophy or disciform scar;\n* Any patient with sub-retinal and\u002For intra-retinal fluid that is not due to CNV (eg, overlying areas of geographic atrophy;\n* Any patient actively being actively treated for Irvine-Gass Syndrome.\n\nExclusion Criteria - Systemic:\n\n* Patient with and\u002For who developed an unstable medical status (e.g., glycemic control, blood pressure, cardiovascular disease, individuals who are unlikely or unable to complete the 9 months trial period) in the opinion of the investigator;\n* Significant renal disease (defined as a serum creatinine \\>2.5 mg\u002FdL);\n* Systolic blood pressure \\>180 mm Hg or diastolic blood pressure \\>110 mm Hg;\n* History of headaches associated with tetracycline therapy\n* History of pseudotumor cerebri;\n* History of tetracycline therapy within the past 6 months;\n* Pregnancy or patient intending to become pregnant within the 9 months of the trial period. For women of child-bearing potential, a pregnancy test will be performed;\n* Sexually active women of child-bearing potential not actively practicing birth control by using a medically accepted device or therapy (i.e., intrauterine device, hormonal contraceptive, or barrier device) during the study period (at least 24 months). This is important as doxycycline may interfere with the effectiveness of hormonal contraceptives. Hence, sexually active women of child-bearing potential who use a hormonal contraceptive will be required to use a second form of contraception to safeguard against contraceptive failure while participating in the study;\n* Known allergy\u002Fintolerance to doxycycline, tetracyclines, or any ingredient in the study drug or placebo;\n* Patients receiving phenytoin, barbiturates, carbamazepine, digoxin, or isotretinoin; patients with gastroparesis; patients with a history of gastrectomy, gastric bypass surgery, or otherwise deemed achlorhydric should all be excluded due to altered doxycycline pharmacokinetics and\u002For bioavailability;\n* Patients taking strontium, acitretin, or tretinoin should excluded due to the potential for serious interactions with doxycycline;\n* Patients with abnormal ALT or AST at baseline will be referred to their primary care physician for medical clearance for participation in this study.","ALL","50 Years","99 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment.\n\nThe investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.",[27,28],"Exudative Macular Degeneration","Wet Age-related Macular Degeneration",[30],"Active choroidal neovascularization (CNV)","RECRUITING","2026-03-27",{"date":34,"type":35},"2026-04-02","ACTUAL",{"date":37,"type":35},"2020-11-04",{"date":39,"type":21},"2027-03-01",{"name":41,"class":42},"University of Iowa","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100446433","phase-4-treatment-of-neovascular-amd-artificial-intelligence-in-real-world-setting-100446433","NCT05093374","Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting","Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study.","Inclusion Criteria\n\n* Adults ≥ 50 years\n* Active neovascular AMD (classic, occult choroidal neovascularization (CNV), RAP lesion or PCV lesion) assessed by OCT, OCTA, FA\n* Patients who have a BCVA score better or equal 0.1 (20\u002F200) in the study eye using ETDRS\n* No significant fibrosis or geographic atrophy (GA) involving the fovea\n* Willingness and ability to comply with study visits and study procedures\n* Signed informed consent form\n\nExclusion Criteria\n\n* Hypersensitivity to Fluoresceine, Ranibizumab, Aflibercept, Brolucizumab or to any of the excipients (Polysorbate 20, Sodium dihydrogen phosphate, monohydrate, Disodium hydrogen phosphate, heptahydrate, Sodium chloride, Sucrose)\n* Any surgical treatment of the eye within 3 months prior to baseline in the study eye\n* History of pseudophakic cystoid macular edema (Irvine Gass Syndrome)\n* History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Visit 0, or a history of post-operative complications within the last 12 months preceding Visit 0 in the study eye (uveitis, cyclitis etc.)\n* History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C\u002FD Ratio \\>0,9\n* Aphakia in the study eye\n* Presence of a retinal pigment epithelial tear involving the macula in the study eye\n* Any concurrent intraocular condition in the study eye (e.g. advanced cataract or diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the twelve-month study period to prevent or treat visual loss that might result from that condition\n* Active intraocular inflammation (grade trace or above) in the study eye\n* Active or suspected ocular or periocular infection in the study eye\n* Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye\n* Current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment\n* Evidence of current infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye\n* Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery) during the study period\n* Presence of corneal decompensation, haze or scaring with an impact on BCVA","100 Years",{"count":53,"type":21},290,[55],"PHASE4","The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits\u002Ftreatments).",[27],"2024-11-21",{"date":60,"type":35},"2024-11-25",{"date":62,"type":35},"2021-03-01",{"date":64,"type":21},"2025-12-31",{"name":66,"class":42},"Medical University of Vienna"]